Pages that link to "Glossary:TAG-00320-Foo-eri"

The following pages link to Glossary:TAG-00320-Foo-eri:

Displaying 50 items.

• Glossary (← links)
• Reference:USA 21 CFR Part 50 09-Apr-2025 § 50.3 (c) (← links)
• Reference:USA 21 CFR Part 56 09-Apr-2025 § 56.110 (a) - (b) (1) (← links)
• Reference:USA 21 CFR Part 320 09-Apr-2025 § 320.22 (← links)
• Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.1 (← links)
• Reference:USA 21 CFR Part 50 09-Apr-2025 § 50.3 (← links)
• Reference:USA 21 CFR Part 56 09-Apr-2025 § 56.104 (d) (← links)
• Reference:USA 21 CFR Part 312 09-Apr-2025 § 312.85 (← links)
• Reference:USA FDA - E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1): Guidance for Industry March 2018 - (← links)
• Reference:USA Acceptance of Clinical Data to Support Medical Device Applications and Submissions Frequently Asked Questions - Guidance for Industry and Food and Drug Administration Staff 21-Feb-2018 - (← links)
• Reference:USA 21 CFR Part 54 09-Apr-2025 § 54.1-001 (← links)
• Reference:USA 21 CFR Part 56 09-Apr-2025 - (← links)
• Reference:USA 21 CFR Part 56 09-Apr-2025 § 56.103 (← links)
• Reference:USA 21 CFR Part 56 09-Apr-2025 § 56.104 (← links)
• Reference:USA 21 CFR Part 56 09-Apr-2025 § 56.105 (← links)
• Reference:USA 21 CFR Part 312 09-Apr-2025 § 312.40 (b) (← links)
• Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.30 (← links)
• Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.42 (← links)
• Reference:USA 21 CFR Part 812 09-Apr-2025 Subpart D (← links)
• Reference:USA 21 CFR Part 312 09-Apr-2025 § 312.62 (← links)
• Reference:USA 21 CFR Part 312 09-Apr-2025 § 312.57-001 (← links)
• Reference:USA 21 CFR Part 812 09-Apr-2025 Subpart G (← links)
• Reference:USA 21 CFR Part 312 09-Apr-2025 § 312.23 (a) ; (6) (← links)
• Reference:USA 21 CFR Part 312 09-Apr-2025 § 312.23 (a) ; (5) (← links)
• Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.27 (← links)
• Reference:USA 21 CFR Part 312 09-Apr-2025 § 312.3 (b) - CRO (← links)
• Reference:USA 21 CFR Part 312 09-Apr-2025 § 312.50 (← links)
• Reference:USA 21 CFR Part 312 09-Apr-2025 § 312.53 (← links)
• Reference:USA 21 CFR Part 54 09-Apr-2025 § 54.4 list of investigators (← links)
• Reference:USA FDA Guidance for Industry - Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring Aug-2013 VI C. (← links)
• Reference:USA 21 CFR Part 54 09-Apr-2025 § 54.4 disclosure (← links)
• Reference:USA 21 CFR Part 312 09-Apr-2025 § 312.53 (c) (vi) (← links)
• Reference:USA 21 CFR Part 312 09-Apr-2025 § 312.60-001 (← links)
• Reference:USA 21 CFR Part 312 09-Apr-2025 § 312.64-001 (← links)
• Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.43 (c) (4) (← links)
• Reference:USA 21 CFR Part 812 09-Apr-2025 Subpart E (← links)
• Reference:USA 21 CFR Part 312 09-Apr-2025 § 312.53 (viii) (← links)
• Reference:USA FDA Guidance for Industry Investigator Responsibilities — Protecting the Rights, Safety, and Welfare of Study Subjects Oct-2009 III. A. (← links)
• Reference:USA 21 CFR Part 312 09-Apr-2025 § 312.53 (c) (← links)
• Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.43 (c) (5) (← links)
• Reference:USA 21 CFR Part 50 09-Apr-2025 § 50.25 (e) (← links)
• Reference:USA 21 CFR Part 312 09-Apr-2025 § 312.60-002 (← links)
• Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.100 (← links)
• Reference:USA FDA Guidance for Industry Investigator Responsibilities — Protecting the Rights, Safety, and Welfare of Study Subjects Oct-2009 III. B. (← links)
• Reference:USA 21 CFR Part 50 09-Apr-2025 § 50.20 (← links)
• Reference:USA 21 CFR Part 50 09-Apr-2025 § 50.22 (← links)
• Reference:USA 21 CFR Part 50 09-Apr-2025 § 50.23 (← links)
• Reference:USA 21 CFR Part 50 09-Apr-2025 § 50.24 (← links)
• Reference:USA 21 CFR Part 50 09-Apr-2025 § 50.25 (a) - (b) (← links)
• Reference:USA 21 CFR Part 50 09-Apr-2025 § 50.27 (← links)